Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Odalys Gonzalez Paz

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Expert Opinion on Drug Safety|June 4, 2011
Anthracycline cardiotoxicityPierantonio Menna, Odalys Gonzalez Paz, Massimo Chello, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 16, 2009
Quantitative prediction of human clearance guiding the development of Raltegravir (MK-0518, isentress) and related HIV integrase inhibitorsRalph Laufer, Odalys Gonzalez Paz, Annalise Di Marco, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 30, 2012
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patientsEmanuela Salvatorelli, Pierantonio Menna, Odalys Gonzalez Paz, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 17, 2012
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicinEmanuela Salvatorelli, Pierantonio Menna, Odalys Gonzalez Paz, et al.
Journal of Medicinal Chemistry|December 13, 2006
4,5-dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical speciesVincenzo Summa, Alessia Petrocchi, Victor G Matassa, et al.
Journal of Medicinal Chemistry|March 29, 2008
A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivoPhilip Jones, Sergio Altamura, Raffaele De Francesco, et al.
Journal of Medicinal Chemistry|May 16, 2009
Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic propertiesOlaf Kinzel, Laura Llauger-Bufi, Giovanna Pescatore, et al.
Journal of Medicinal Chemistry|December 15, 2020
Cyclic Phosphopantothenic Acid Prodrugs for Treatment of Pantothenate Kinase-Associated NeurodegenerationGiulio Auciello, Annalise Di Marco, Odalys Gonzalez Paz, et al.
International Journal of Molecular Sciences|July 27, 2022
Modelling the Human Blood-Brain Barrier in Huntington DiseaseDomenico Vignone, Odalys Gonzalez Paz, Ivan Fini, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2004
SAR and pharmacokinetic studies on phenethylamide inhibitors of the hepatitis C virus NS3/NS4A serine proteaseSavina Malancona, Stefania Colarusso, Jesus M Ontoria, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Expert Opinion on Drug Safety|June 4, 2011
Anthracycline cardiotoxicityPierantonio Menna, Odalys Gonzalez Paz, Massimo Chello, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 16, 2009
Quantitative prediction of human clearance guiding the development of Raltegravir (MK-0518, isentress) and related HIV integrase inhibitorsRalph Laufer, Odalys Gonzalez Paz, Annalise Di Marco, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 30, 2012
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patientsEmanuela Salvatorelli, Pierantonio Menna, Odalys Gonzalez Paz, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 17, 2012
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicinEmanuela Salvatorelli, Pierantonio Menna, Odalys Gonzalez Paz, et al.
Journal of Medicinal Chemistry|December 13, 2006
4,5-dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical speciesVincenzo Summa, Alessia Petrocchi, Victor G Matassa, et al.
Journal of Medicinal Chemistry|March 29, 2008
A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivoPhilip Jones, Sergio Altamura, Raffaele De Francesco, et al.
Journal of Medicinal Chemistry|May 16, 2009
Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic propertiesOlaf Kinzel, Laura Llauger-Bufi, Giovanna Pescatore, et al.
Journal of Medicinal Chemistry|December 15, 2020
Cyclic Phosphopantothenic Acid Prodrugs for Treatment of Pantothenate Kinase-Associated NeurodegenerationGiulio Auciello, Annalise Di Marco, Odalys Gonzalez Paz, et al.
International Journal of Molecular Sciences|July 27, 2022
Modelling the Human Blood-Brain Barrier in Huntington DiseaseDomenico Vignone, Odalys Gonzalez Paz, Ivan Fini, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2004
SAR and pharmacokinetic studies on phenethylamide inhibitors of the hepatitis C virus NS3/NS4A serine proteaseSavina Malancona, Stefania Colarusso, Jesus M Ontoria, et al.
Pageof 2